Physician profile
Archana Bindra
NPI 1225066947
$69,778.96
in general payments reported to CMS, 2019-2025
21 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $94.71 · 2021: $102 · 2022: $112 · 2023: $32K · 2024: $6,720 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Travel and Lodging: $12K · Consulting Fee: $4,800 · Food and Beverage: $3,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,962.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,575.00 |
| Travel and Lodging | $11,804.60 |
| Consulting Fee | $4,800.00 |
| Food and Beverage | $3,893.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47,356.25 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $20,569.43 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $573.14 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $257.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $174.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.65 | 2019 | |
| Merck Sharp & Dohme LLC | $121.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $109.80 | 2019 | |
| Livanova USA, INC. | $84.38 | 2019 | |
| Amgen INC. | $78.87 | 2019 | |
| Akcea Therapeutics, INC. | $55.21 | 2019 | |
| Amarin Pharma, INC. | $52.38 | 2019 | |
| Dexcom, INC. | $51.71 | 2022-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $35.57 | 2019 | |
| Medtronic, INC. | $30.84 | 2025 | Minimed 780g |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.11 | 2019 | |
| Companion Medical, INC. | $15.86 | 2019 | |
| Corcept Therapeutics | $14.33 | 2019 | |
| Mannkind Corporation | $14.16 | 2019 | |
| Insulet Corporation | $12.84 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.